New drug trial offers hope for women with advanced cervical cancer
NCT ID NCT01676818
Summary
This study tested whether the chemotherapy drug eribulin could help control advanced or recurrent cervical cancer. Thirty-two women with cervical cancer that had spread or returned after treatment received eribulin infusions every three weeks. Researchers measured how long the cancer stayed under control and monitored side effects to see if this treatment could be a new option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.